Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
about
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody responsePolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsA Blueprint for HIV Vaccine DiscoveryAntibody responses to envelope glycoproteins in HIV-1 infectionThe Antibody Response against HIV-1Virological features associated with the development of broadly neutralizing antibodies to HIV-1Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding siteDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityA Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesInteractions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing ActivityStructural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityStabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoproteinAn efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodiesCross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env GeneHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesInternational network for comparison of HIV neutralization assays: the NeutNet report IIElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinPrevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesRational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1.Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesThe cat and mouse of HIV-1 antibody escape.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinAnalysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesInfluence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primatesHIV-1 vaccine development after STEP.
P2860
Q21090490-EFFC223B-F97F-48EC-AFBF-8E7D4F504BE8Q24635002-9A0BA66C-48C0-4BF2-B52C-94EC0D1EB154Q26829865-4046EEC3-9C4F-4A81-A0D3-30AC4DE02A9BQ26991572-C1019615-2170-4DA5-9964-8D1392E4A8FFQ27000889-FBA3236B-712B-40DB-BD0D-15034A3FD550Q27025177-E6DBEC28-0C13-4B3D-AC49-460D6F93B46CQ27316899-D1213D6F-B02F-4748-B543-68B248B50E9EQ27654848-991A94B2-D616-4BCF-8D82-F3DAC45BF2D3Q27655865-03BDBD45-4A54-4636-9168-868C4CB4D444Q27658138-EAFCB24A-235C-4965-8442-5DA0D2453CD6Q27658449-D1F2D5CF-B3B1-4C49-97DE-3C3808E5E016Q27662155-8DF79CD7-61F6-4ADB-8ADD-43A2AB7DED7DQ27662167-C39D9D0B-D02B-43AC-ADBF-9212E0E0A8E4Q27663293-A6D66722-5084-4CFE-9A7C-E9F37015265DQ27680125-DBC3C4A9-441C-45E2-9E0F-E2A971708F1DQ27684578-8FCCC6CB-7DA3-48C1-868A-4F9121653234Q28483205-B669496A-94C4-4428-A4EB-4D8EA8F815CFQ28484544-E4C5068C-8142-47C8-9E4E-DE98B65E2303Q28534454-45ED383D-8591-4B08-BDCA-2C6CF5B40A1AQ28545185-D92A80AD-A1A4-41F0-BAA6-6ED9B02F923BQ28554907-1B285E1A-705A-4405-82A7-7B8A6A6689EAQ28602877-E92E8508-5AE0-4CF8-BDF4-EB0611EBB0EFQ28730045-89244E80-1E69-4996-899B-B4BF9D220C5CQ28732438-A6588D67-5280-45B5-812C-FDA4A6A4F787Q28742137-3F3A9902-A47A-4FE3-BA6E-30B59DAC755CQ28752503-6414A395-2B47-4E01-A9AF-D6A6CE0BEBCCQ29619511-B09F9F6E-BBE6-4BDB-AE05-F6D8105D0323Q30234577-E4FC4F1F-66F2-471C-9F30-50B224F99644Q30391094-A9704A13-81E8-4E8C-8220-FC8ECDF31E21Q30395868-78D361C2-9672-4E33-911F-9E88ADF57B86Q30408097-1F2C6BE7-EAB8-4CA0-BC3B-0002C7F6726AQ33504607-5F407983-88AD-4C09-8737-F1579A532966Q33518005-4F0CF49B-9865-4DA7-A423-312047F0788EQ33522232-1D060586-FC26-4E8A-8E14-8FED7D6D4019Q33526340-5C149AB1-71C3-4B91-A012-D59F4B7B8587Q33558279-88D505BC-7D99-4FBE-964A-87B386F9F77FQ33594304-769E524C-FA87-4FA0-8AB0-0CF4CF505D88Q33614495-F02088A9-A2B2-424D-8F0D-FB6163CA4A42Q33614605-B455A8A6-CAC6-424A-A74B-FE179D6C8759Q33642318-44E2ACD3-4C68-4196-85C8-4D8CC366070A
P2860
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Analysis of neutralization spe ...... s type 1-infected individuals.
@en
Analysis of neutralization spe ...... s type 1-infected individuals.
@nl
type
label
Analysis of neutralization spe ...... s type 1-infected individuals.
@en
Analysis of neutralization spe ...... s type 1-infected individuals.
@nl
prefLabel
Analysis of neutralization spe ...... s type 1-infected individuals.
@en
Analysis of neutralization spe ...... s type 1-infected individuals.
@nl
P2093
P2860
P356
P1433
P1476
Analysis of neutralization spe ...... s type 1-infected individuals.
@en
P2093
Adhuna Phogat
Diane Wycuff
James Hoxie
Krisha Svehla
Mark Connors
Mark K Louder
Richard Wyatt
Sanjay Phogat
Stephen A Migueles
P2860
P304
P356
10.1128/JVI.01992-08
P407
P577
2008-11-12T00:00:00Z